Aromatase inhibitors are established breast cancer chemoprevention interventions. However, nonadherence remains a significant challenge. We investigated the association between worsening menopause-specific quality of life, baseline participant characteristics, and early treatment discontinuation within the Mammary Prevention.3 (MAP.3) breast cancer prevention trial.
INTRODUCTION
Breast cancer is the most common malignancy in women worldwide, representing 25% of all incident cancers and 14% of cancer-related deaths among women. 1 In clinical trials, both selective estrogen-receptor modulators and aromatase inhibitors have been demonstrated to be efficacious chemoprevention agents for primary prevention in women at high risk for breast cancer. [2] [3] [4] [5] [6] Nonetheless, chemoprevention is vastly underused in the clinical setting and many women who do begin chemoprevention are not fully adherent. 7, 8 Medication nonadherence, which includes noninitiation, poor compliance, and discontinuation, is an important issue because it can reduce the effectiveness of these agents in preventing breast cancer. Currently, information on factors associated with aromatase-inhibitor nonadherence in the prevention setting is limited. In both the adjuvant and prevention settings, a number of patient, treatment, provider, and health-system characteristics have been associated with early treatment discontinuation. [8] [9] [10] In chemoprevention trials, the most commonly cited reason for early discontinuation is intolerable adverse effects. 10, 11 Adverse effects are known to affect quality of life (QOL), which is increasingly recognized as an important clinical outcome. [12] [13] [14] Maunsell et al, 15 reporting on the QOL experiences of women participating in the Mammary Prevention.3 (MAP.3) trial, concluded that exemestane generally had only small negative effects on both menopausespecific and general QOL because negative effects among women taking exemestane were not much greater than those reported by women assigned to placebo. However, among women receiving exemestane or placebo, considerable proportions (up to 44%), reported they had experienced a clinically meaningful worsening in QOL since baseline within the first 12 months on study. 15 The first year after random assignment to treatment group was also the period during which there was a noticeable discrepancy in treatment discontinuation between the trial arms. 5, 15 In this secondary analysis of the MAP.3 trial, we evaluated the association between worsening menopause-specific QOL and early discontinuation of study treatment, meaning discontinuation by 1 year after treatment initiation. Discontinuation of study treatment within this period is clinically relevant because the potential benefits of chemoprevention are likely to be lost. We focused on menopause-specific QOL, as assessed by the Menopause-Specific Quality of Life Questionnaire (MENQOL), because menopausal symptoms are highly prevalent in this population and are one of the most commonly cited reasons for discontinuing endocrine therapy. 5, 6, 8 An additional objective was to identify baseline participant characteristics associated with an increased likelihood of early discontinuation.
METHODS

Overview of the Canadian Cancer Trials Group MAP.3 Trial
The Canadian Cancer Trials Group MAP.3 trial was a phase III, international, randomized, placebo-controlled trial evaluating exemestane, a steroidal aromatase inhibitor, for breast cancer prevention in postmenopausal women. 5 Between September 2004 and March 2010, 4,560 women were randomly assigned to receive exemestane (25 mg) or placebo taken orally daily for 5 years. The primary end point was invasive breast cancer incidence. Full details of the MAP.3 trial have been reported elsewhere. 5 
Study Participants
Postmenopausal women at high risk for breast cancer were eligible for MAP.3 if they were $ 50 years of age with no menses within the past 12 months or age , 50 years with no menses within the past 12 months and with follicle-stimulating hormone levels within the menopausal range. In addition, women were eligible if they had at least one of the following breast cancer risk factors: age $ 60 years, Gail score . 1.66%, or a prior diagnosis of benign breast disease. Health regulatory authorities and institutional review boards at participating centers approved the trial. All participants gave written, informed consent.
Assessment of Menopause-Specific QOL
Menopause-specific QOL was assessed using the MENQOL upon trial entry and 6 months after random allocation. The MENQOL, a selfadministered instrument, assesses the presence and severity of menopause-specific symptoms within the last 4 weeks. 16, 17 The MENQOL has 29 items that aggregate into one of four domains: vasomotor (three items), sexual (three items), physical (seven items), and psychosocial (16 items) functioning. Participants are asked to rank the presence and level of bother from their symptoms on a 7-point Likert scale, with higher scores corresponding to a higher level of bothersome symptoms. The MENQOL has been demonstrated to be a valid, reliable, and responsive instrument for assessing menopause-specific QOL.
17 MENQOL domain scores were calculated for each participant who responded to more than 50% of the items in a given MENQOL domain. A summary score for overall menopause-specific QOL was computed by averaging the scores from each domain for participants with three or more available domain scores. 16 
Baseline Participant Characteristics
Information on sociodemographic, medical history, lifestyle, and breast cancer risk factors was collected at baseline with standardized selfreport instruments. The Charlson Comorbidity Index score, 18 total number of concomitant medications, current use of calcium and bisphosphonate supplements, and previous use of selective estrogenreceptor modulators were also considered.
Outcome Assessment
Early discontinuation of study treatment (exemestane or placebo), defined as stopping assigned study medication within 365 days of being randomly allocated to a treatment group, was the primary outcome. Participants who stopped treatment because of a breast event were not considered to have discontinued and were excluded from this analysis. Participants informed study staff that they had discontinued study treatment during clinical assessment visits that occurred at 6 and 12 months after being randomly allocated to a treatment. For those who reported discontinuing study treatment, the date of the last dose and reason for discontinuation were recorded.
Statistical Analyses
All participants initially enrolled in the MAP.3 trial who completed a baseline MENQOL were eligible for inclusion in this secondary analysis. The baseline characteristics of participants who did and did not discontinue within 1 year of randomization were compared using x 2 and t tests. A clinically meaningful worsening in overall menopause-specific QOL from baseline to 6 months postrandomization was the primary exposure of interest in this analysis. Those with a score increase of $ 0.5 points out of 8 in the overall summary score from baseline during this period were classified as having a clinically meaningful worsening in QOL, whereas those with a , 0.5-point increase were considered as not having worsened QOL. The occurrence of a clinically meaningful worsening in each individual domain of the MENQOL was also determined in the same way. A score change corresponding to at least 5% to 10% in a scale's overall breadth is a definition of clinically meaningful change commonly used in the QOL literature. [19] [20] [21] For the MENQOL, this $ 0.5-point criterion corresponds with a 6.25% score change, and was used in our previous report on QOL in MAP. 3. 15 Log-binomial regression models adjusted for assignment to exemestane or not, for each domain of the MENQOL and overall menopause-specific QOL, were used to assess the association between clinically meaningful worsening and discontinuation of study treatment within the first year of study. Given that the time when worsening in menopause-specific QOL was measured may have varied in relation to the actual time treatment was discontinued, sensitivity analyses by time since discontinuation were performed to account for this potential discrepancy. For the primary association (ie, between worsening and discontinuation), multiplicative effect modification by study treatment (exemestane or placebo), was assessed using an interaction term.
In addition to a worsening in overall menopause-specific QOL, baseline participant characteristics were considered as potential explanatory variables of early treatment discontinuation. First, log-binomial regression analysis was used to generate crude (unadjusted) relative risks (RRs), 95% CIs and P values for these other predetermined variables of interest and of early study treatment discontinuation. Variables that met the screening criteria (Wald P # .25) were then considered for inclusion in the final multivariable model, along with worsening in overall menopause-specific QOL. The final model consisted of factors associated with early treatment discontinuation, mutually adjusted for one another. All statistical analyses were carried out using SAS software, version 9.3 (SAS Institute, Cary, NC). Statistical significance was defined as P # .05.
RESULTS
MAP.3 participants included were predominantly white, between the ages of 60 and 74 years, and never smokers (Table 1) . Of the 4,560 women originally enrolled in the trial, 11 experienced a breast event within the first year of study and 49 did not submit a baseline MENQOL, leaving 4,501 eligible for this analysis (Fig 1) . By year 1, 724 participants (17%) discontinued assigned treatment (19% of the exemestane group and 13% of the placebo group). Of the 724 participants who discontinued treatment by 1 year, 553 (76%) completed a 6-month MENQOL, among whom 151 (27%) completed it within 1 month of discontinuing and 402 (73%) completed it outside this time window. Worsening in overall menopause-specific QOL was experienced by 1,000 participants (24%), and approximately 35%, 19%, 28%, and 27% of women experienced a clinically meaningful worsening in the vasomotor, sexual, physical, and psychosocial domains, respectively, within the first 6 months of being randomly assigned to a treatment group.
Women who experienced a worsening in any of the MENQOL domains within 6 months of treatment assignment were significantly more likely to discontinue treatment within the first year compared with those who did not (Table 2) . A worsening in overall menopause-specific QOL was also significantly associated with discontinuation of assigned treatment within the first year (RR, 1.79; 95% CI, 1.53 to 2.10). The association between worsening in overall menopause-specific QOL and early treatment discontinuation was not modified by assignment to exemestane (P for interaction = .53). When restricting the analysis to participants who completed the MENQOL within 1 month of discontinuation, the strength of associations between worsening in all domains of the MENQOL and early treatment discontinuation increased and remained statistically significant (Table 2) . For those who completed the MENQOL more than 1 month after discontinuation, the associations between worsening and discontinuation were weaker but still statistically significant (data not shown).
When considered simultaneously with other participant characteristics, a worsening in overall menopause-specific QOL was the strongest risk factor for treatment discontinuation within the first year of study (RR, 1.76; 95% CI, 1.48 to 2.09; Table 3 ). Those assigned to exemestane were 59% more likely to discontinue the drug within the first year after being randomly assigned to that treatment group compared with those assigned to placebo (RR, 1.59; 95% CI, 1.33 to 1.90). Being currently used was the only sociodemographic characteristic among those considered that was significantly associated with early discontinuation of treatment (RR, 1.22; 95% CI, 1.01 to 1.47). Previous and current smokers were 22% and 39%, respectively, more likely to discontinue treatment as compared with never-smokers (past-smoker RR, 1.22 [95% CI, 1.02 to 1.45]; current-smoker RR, 1.39 [95% CI, 1.00 to 1.91]).
DISCUSSION
Independently of whether women had been assigned to receive exemestane, healthy postmenopausal women who experienced a clinically meaningful worsening in menopause-specific QOL while taking the study medication were more likely to discontinue study treatment within the first year of study when compared with women who did not experience worsening. In fact, this association did not vary significantly when treatment assignment was considered as an effect modifier. Although exemestane allocation, current employment, and past or current smoking status at baseline were also positively associated with discontinuation within the same period, in adjusted analyses where all factors associated with treatment discontinuation were considered simultaneously, a worsening in overall menopausespecific QOL remained the strongest risk factor for early discontinuation. In a placebo-controlled breast cancer prevention trial evaluating an intervention not yet proven at that time to decrease breast cancer incidence, it is not surprising that a decline in QOL would influence a woman's decision to stop taking her assigned treatment.
Our findings highlight the recently recognized importance of symptoms in women receiving endocrine therapy being misattributed as resulting from being adherent to the medication. 22 Worsening of symptoms captured by the MEN-QOL that met the a priori definition of clinical importance to qualify as a negative impact on menopause-specific QOL were commonly reported by participants in both the placebo and exemestane groups. However, differences in symptom levels between randomization groups were generally smaller than ones considered clinically important. 15 Furthermore, worsening of menopausal symptoms was associated with study medication discontinuation in both placebo and exemestane groups. From a clinical perspective, the results also suggest that attention to such menopausal symptoms, even when not caused by the aromatase inhibitor, may improve QOL and medication adherence as well.
Symptoms and QOL were also examined as predictors of chemoprevention adherence to tamoxifen in the National Surgical Breast and Bowel Project P-1 trial. 23 Despite the difference in adverse effects of the two evaluated agents and the inclusion of premenopausal women in P-1, in some ways, the findings with tamoxifen in P-1 are similar to the findings with exemestane in MAP3. P-1 participants were pre-and postmenopausal women at increased breast cancer risk who were randomly assigned to receive daily tamoxifen or placebo. Baseline and 3-month postrandomization Short Form-36 QOL findings and participant symptoms (ie, gynecologic, vasomotor, sexual, and other) were examined in relation to 12-month drug adherence, which was defined as a composite of compliance and early discontinuation. By 12 months, 15.7% of participants were not adherent with their assigned treatment (placebo or tamoxifen). A higher baseline Short Form-36 mental component score (ie, better mental wellbeing) was positively associated with 12-month adherence, whereas baseline vasomotor symptoms among those assigned to tamoxifen and 3-month sexual symptoms in younger women were negatively associated with 12-month adherence. The strongest association with discontinuation was with other symptoms. The message from both reports is similar, namely, attention to early symptoms, which can negatively influence QOL, regardless of their etiology, is a strategy with potential to improve chemoprevention adherence. In other analyses from the P-1 trial, participant characteristics, including age, education, income, race, and risk of breast cancer, were identified as predictors of tamoxifen adherence. 24 These associations were not found in our current MAP.3 analyses examining 12-month discontinuation rate and may be a result of the difference in the definitions of adherence used between the two studies.
Within chemoprevention trials, arthralgia and menopausal symptoms are two commonly reported complaints among those taking aromatase inhibitors. 25 Interestingly, women not taking aromatase inhibitors (ie, those receiving placebo) also frequently have reported these symptoms. Although the focus of the current report from MAP.3 was on worsening menopause-specific QOL and early discontinuation of study treatment, an exploratory analysis of the IBIS-II (International Breast Cancer Intervention Studies-II) placebo-controlled prevention trial evaluating anastrozole reported similar findings with respect to arthralgia and discontinuation. 26 In IBIS-II, arthralgia was common regardless of randomization group (moderate/severe in 55% of those receiving placebo and in 59% of women receiving anastrozole) and severe arthralgias led to significantly more withdrawals, again regardless of randomization group. As in MAP.3, in IBIS-II, participants in both the placebo and aromatase inhibitor groups attached their bothersome symptoms to the aromatase inhibitor, subsequently leading to treatment discontinuation. Together, observations from both trials indicate that in the clinic, symptoms in women using aromatase inhibitors are commonly those associated with aging and the menopause itself. In any case, successful management of such symptoms is likely to enhance adherence in any clinical setting.
Being a smoker at study entry was a significant determinant of early discontinuation. Smoking has been found to increase the risk of vasomotor, physical, and psychologic symptoms commonly experienced during and after menopause. 27, 28 Smokers in the placebo group may have incorrectly attributed these symptoms to study treatment, prompting them to discontinue. Smoking is known to exacerbate the symptoms of endocrine therapy; however, a post hoc test for the interaction between worsened QOL and smoking status on early discontinuation was not statistically significant, although power for such an analysis was low. Women who were currently employed at baseline were more likely to discontinue treatment than their unemployed counterparts. One may speculate that employed women may have a lower tolerance for †For each domain, the number of participants included in the analysis of worsened menopause-specific QOL and early discontinuation varied because not all participants completed more than 50% of the items in a particular domain to allow the calculation of a domain score.
‡Adjusted for treatment assignment (placebo or exemestane). RR was calculated using the log-binomial regression equation log(P) = b 0 + b 1 X 1 + b 2 X 2, where P = probability of discontinuing study treatment within 12 months of initiation, X 1 = worsened menopause-specific QOL, and X 2 = treatment assignment. symptoms if the symptoms negatively impact their daily routine, causing the women to prematurely discontinue treatment. Our study has limitations. Information about treatment discontinuation was based on self-report and may have been subject to some misclassification. It is unlikely women would falsely report treatment discontinuation. However, if women who claimed to be continuing treatment had, in fact, stopped, our study would have underestimated the discontinuation percentage. If those discontinuing treatment also experienced a worsening in menopausespecific QOL, then the effect estimates may have been an underestimate of the true effect. We were unable to examine the potential associations between alcohol use, physical activity, personal perceptions about chemoprevention, and treatment discontinuation, because this information was not routinely collected. Information on patients' characteristics was mainly collected at baseline; therefore, we were unable to assess how changes in modifiable factors such as body mass index, smoking status, and concomitant medication use may have affected treatment discontinuation. Finally, most participants were white, nonsmokers, and had postsecondary education, which may affect the generalizability of our findings.
Our study also has strengths. To our knowledge, examining associations between changes over time in QOL, as well as other potential explanatory factors, and early discontinuation of aromatase-inhibitor therapy has not been addressed in the breast cancer prevention setting. Baseline data on participant characteristics examined here were nearly complete and collected systematically through study blinding to group assignment. QOL information was derived from the MENQOL, established as a valid, reliable, and sensitive instrument in the postmenopausal population.
Overall completion of the health-related QOL instruments at baseline and 6 months postrandomization was high, suggesting that our results represent the experiences of the majority of trial participants.
In conclusion, although the efficacy of chemoprevention agents has been established, the benefits of chemoprevention as a primary prevention strategy in clinical practice for women at high risk for breast cancer will largely depend on the uptake of and adherence to these agents. This study addresses the extreme form of nonadherence, discontinuation, within the context of a clinical trial. Negative changes in menopause-specific QOL influence a woman's decision to stop taking chemoprevention therapy. Attention to such symptoms may improve QOL and potentially improve chemoprevention adherence.
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